SBI Securities’s Design Therapeutics DSGN Stock Holding History

SBI Securities’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$145	Buy	+10	New	+$125	﹤0.01%	3415

Other funds holding DSGN

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Allied Private Wealth Boca Raton, Florida $156M AUM

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

SBI Securities's DSGN Position: Q2 2026 in Review

SBI Securities opened a new position in Design Therapeutics (DSGN) in Q2 2026: 10 shares worth $145. The stake represents ﹤0.01% of the portfolio and ranks #3415 among its holdings.

13 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

SBI Securities held 10 shares of Design Therapeutics worth $145 as of Q2 2026.
Design Therapeutics was a new SBI Securities position in Q2 2026.
Design Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3415 holding.
13 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.